Sanofi US News

Sanofi launches Beyfortus® (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.

Bridgewater, N.J., February 1, 2024. Sanofi continues to engage with its manufacturing partner AstraZeneca, government officials, healthcare providers and others in the U.S. to help ensure available Beyfortus® (nirsevimab-alip) 50mg and 100mg Injection doses reach eligible babies for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease.

Currently, insurance coverage is in place for nearly 100% of infant lives in the U.S. To help facilitate ongoing access to available doses for eligible babies, Sanofi continues to work closely with providers in the private market and the Vaccines for Children (VFC) program to best support the communities they serve. Nearly 40% of eligible babies could have the ability to be immunized against RSV with Beyfortus this RSV season.

Knowing the critical role providers have in helping to protect as many babies as possible from RSV, Sanofi has established the Beyfortus Reservation Program to further strengthen customer collaboration in support of improved readiness for the 2024-2025 RSV season. The Beyfortus Reservation Program provides critical insight on customer demand and allows for prioritized fulfillment of requests placed through this program. It offers providers   flexibility in scheduling shipments and the ability to cancel orders within terms.

Ayanna Santos, Pharm.D.
Head of RSV Franchise, U.S. Vaccines, Sanofi
“We are focusing on how we partner with customers with the aim of protecting babies from the leading cause of infant hospitalization in the U.S. We’re excited by the potential of the Beyfortus Reservation Program to help support planning for the next RSV season.” 

For those who order outside of the Beyfortus Reservation Program, the normal order window will be available from September 2024 through February 2025. The Beyfortus Reservation Program is not applicable to the VFC program, and Sanofi continues to engage with the Centers for Disease Control and Prevention to ensure supply for the VFC program. Providers should consult their state or local VFC program to order Beyfortus for their VFC patients for the 2024-2025 season.

Beyond the Beyfortus Reservation Program for the private market, Sanofi is also taking additional measures to help ensure greater preparedness for the 2024-2025 season. Sanofi will continue to work with AstraZeneca to expand the Beyfortus manufacturing network to allow for a significant increase in supply for the 2024-2025 season and cover the entire U.S. demand. Beyfortus is being manufactured well in advance of the RSV season, with the vast majority of doses expected to be available before October.

For private customers who are interested in participating in the Beyfortus Reservation Program, they should contact their Sanofi representative or request a representative at

Sanofi appreciates its ongoing collaboration with government agencies and looks forward to working with providers to reach our shared ambition to protect as many babies as possible against RSV.


Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in:

  • Newborns and babies under 1 year of age born during or entering their first RSV season.
  • Children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season.


Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus.

Before your child receives Beyfortus, tell your healthcare provider about all of your child’s medical conditions, including if your child:

  • has ever had a reaction to Beyfortus.
  • has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem.

Tell your healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received Beyfortus in the same RSV season.

Serious allergic reactions have happened with other medicines like Beyfortus. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction:

  • swelling of the face, mouth, or tongue
  • difficulty swallowing or breathing
  • unresponsiveness
  • bluish color of skin, lips, or under fingernails
  • muscle weakness
  • severe rash, hives, or itching

The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the site of your child’s injection. These are not all the possible side effects of Beyfortus. Call your healthcare provider if you have questions about side effects.

Please see full Prescribing Information, including Patient Information for more details.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Evan Berland | +1 215 432 0234 |

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.